Zydus Cadila muscle relaxant injection Cisatracurium Besylate gets USFDA okay
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.
Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration.
It is an adjunct to general anaesthesia to facilitate tracheal intubation in adults and in paediatric patients 1 month to 12 years of age and to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU.
The drug will be manufactured at Liva plant of Cadila Healthcare Limited.
The group now has 297 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Bharat Biotech, Zydus Cadila COVID-19 vaccine in phase 2 trial, says VK Paul
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.